Summary
Background Afatinib, an irreversible ErbB family blocker, has shown synergistic antitumor activity and manageable tolerability in combination with chemotherapy. This phase I study assessed oral afatinib plus intravenous gemcitabine or docetaxel in patients with relapsed/refractory solid tumors. Methods Patients received afatinib (30, 40, or 50 mg) plus gemcitabine (1000 or 1250 mg/m2) or docetaxel (60 or 75 mg/m2). Dose escalation proceeded via a 3 + 3 design until the maximum tolerated dose (MTD) was reached. Adverse events (AEs), pharmacokinetics and antitumor activity were also assessed. Results Dose-limiting toxicities during Cycle 1 were reported in 6/39 patients receiving afatinib/gemcitabine (most commonly diarrhea, thrombocytopenia and vomiting) and 16/54 patients receiving afatinib/docetaxel (most commonly febrile neutropenia and stomatitis). The MTDs were established as afatinib 40 mg/gemcitabine 1000 mg/m2 and afatinib 30 mg/docetaxel 60 mg/m2. The most common drug-related AEs were diarrhea, asthenia and rash with afatinib/gemcitabine, and diarrhea, asthenia and stomatitis with afatinib/docetaxel. No relevant pharmacokinetic interactions were observed for either combination. Both combinations demonstrated clinical activity and durable disease control at the MTDs. Compared with the MTD, higher response rates were achieved with afatinib 30 mg/docetaxel 75 mg/m2 (28% vs 6%); however, this regimen was associated with problematic febrile neutropenia, an expected AE with docetaxel, that is often managed with growth factor support. Conclusions Afatinib/gemcitabine and afatinib/docetaxel demonstrated manageable safety profiles, with evidence of clinical efficacy at the MTDs. For afatinib/docetaxel, a dose level of afatinib 30 mg/docetaxel 75 mg/m2 produced higher response rates. Trial registration: NCT01251653 (ClinicalTrials.gov).
Similar content being viewed by others
References
Li D, Ambrogio L, Shimamura T et al (2008) BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27(34):4702–4711. https://doi.org/10.1038/onc.2008.109
Solca F, Dahl G, Zoephel A et al (2012) Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 343(2):342–350. https://doi.org/10.1124/jpet.112.197756
Sequist LV, Yang JC, Yamamoto N et al (2013) Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31(27):3327–3334. https://doi.org/10.1200/JCO.2012.44.2806
Soria JC, Felip E, Cobo M et al (2015) Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol 16(8):897–907. https://doi.org/10.1016/S1470-2045(15)00006-6
Wu YL, Zhou C, Hu CP et al (2014) Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 15(2):213–222. https://doi.org/10.1016/S1470-2045(13)70604-1
(2013) PaMDA (2016) Japan new drug approvals 2013. Accessed 8 Mar 2018. http://www.pmda.go.jp/files/000153463.pdf
Administration USFaD (2013) GILOTRIF™(afatinib) tablets, for oral use (revised 07/2013). http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/201292s000lbl.pdf
Agency EM (2016) Giotrif European Public Assessment Report (updated 01/2016). www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002280/human_med_001698.jsp&mid=WC0b01ac058001d124
Choudhury NJ, Campanile A, Antic T et al (2016) Afatinib activity in platinum-refractory metastatic urothelial carcinoma in patients with ERBB alterations. J Clin Oncol 34(18):2165–2171. https://doi.org/10.1200/JCO.2015.66.3047
Machiels JP, Haddad RI, Fayette J et al (2015) Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol 16(5):583–594. https://doi.org/10.1016/S1470-2045(15)70124-5
Seiwert TY, Fayette J, Cupissol D et al (2014) A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck. Ann Oncol 25(9):1813–1820. https://doi.org/10.1093/annonc/mdu216
Janjigian YY, Viola-Villegas N, Holland JP et al (2013) Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET. J Nucl Med 54(6):936–943. https://doi.org/10.2967/jnumed.112.110239
Schutze C, Dorfler A, Eicheler W et al (2007) Combination of EGFR/HER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with irradiation in FaDu human squamous cell carcinoma. Strahlenther Onkol 183(5):256–264. https://doi.org/10.1007/s00066-007-1696-z
Schwab CL, Bellone S, English DP et al (2014) Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo. Br J Cancer 111(9):1750–1756. https://doi.org/10.1038/bjc.2014.519
Solca F, Baum A, Himmelsbach A, Amelsberg A, Adolf G (2006) Efficacy of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in combination with cytotoxic agents. Eur J Cancer Suppl 4(12):Poster 567
Ioannou N, Dalgleish AG, Seddon AM et al (2011) Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells. Br J Cancer 105(10):1554–1562. https://doi.org/10.1038/bjc.2011.396
Khelwatty SA, Essapen S, Seddon AM, Modjtahedi H (2011) Growth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992), an irreversible erbB family blocker, and its association with expression of HER family members. Int J Oncol 39(2):483–491. https://doi.org/10.3892/ijo.2011.1054
Takezawa K, Okamoto I, Tanizaki J et al (2010) Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor. Mol Cancer Ther 9(6):1647–1656. https://doi.org/10.1158/1535-7163.MCT-09-1009
Xue C, Tian Y, Zhang J et al (2016) In vitro and in vivo efficacy of afatinib as a single agent or in combination with gemcitabine for the treatment of nasopharyngeal carcinoma. Drug Des Devel Ther 10:1299–1306. https://doi.org/10.2147/DDDT.S94432
Vermorken JB, Rottey S, Ehrnrooth E et al (2013) A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors. Ann Oncol 24(5):1392–1400. https://doi.org/10.1093/annonc/mds633
Awada AH, Dumez H, Hendlisz A et al (2013) Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors. Invest New Drugs 31(3):734–741. https://doi.org/10.1007/s10637-012-9880-0
Marshall J, Shapiro GI, Uttenreuther-Fischer M et al (2013) Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer. Future Oncol 9(2):271–281. https://doi.org/10.2217/fon.12.195
Administration USFaD (2014) GEMZAR (gemcitabine for injection) Powder, Lyophilized, For Solution For Intravenous Use (revised 5/2014). www.accessdata.fda.gov/drugsatfda_docs/label/2014/020509s077lbl.pdf
Administration USFaD (2013) TAXOTERE (docetaxel) Injection Concentrate, Intravenous Infusion (revised 12/2013). www.accessdata.fda.gov/drugsatfda_docs/label/2013/020449s071lbl.pdf
Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247. https://doi.org/10.1016/j.ejca.2008.10.026
Aapro M, Crawford J, Kamioner D (2010) Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now? Support Care Cancer 18(5):529–541. https://doi.org/10.1007/s00520-010-0816-y
Park K, Tan EH, O'Byrne K et al (2016) Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. https://doi.org/10.1016/S1470-2045(16)30033-X
Acknowledgments
The authors would like to thank the patients, their families, and the investigators and staff at all clinical sites for their valuable contributions to this study. This trial was sponsored by Boehringer Ingelheim. The sponsor was involved in the study design, data collection, data analysis, reporting of the results, and preparation of the manuscript. The authors were fully responsible for all content and editorial decisions, were involved at all stages of manuscript development, and approved the final version for submission. Medical writing assistance, supported financially by Boehringer Ingelheim, was provided by Fiona Scott of GeoMed, an Ashfield company, part of UDG Healthcare plc, during the preparation of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
The study was conducted in accordance with the ethical principles of the Declaration of Helsinki, and Good Clinical Practice as defined by the International Conference on Harmonization. The study was approved by the relevant local Institutional Review Boards and/or Independent Ethics Committees, and informed consent was obtained from all individual participants included in the study.
Conflicts of interest
CG-R has participated in advisory boards for Astra-Zeneca, BMS and Novartis. JB has participated in advisory boards for BMS, Boehringer Ingelheim, Astra Zeneca and Roche. JF and MS were employees of Boehringer Ingelheim at the time of study conduct. HdM-S and DS are current employees of Boehringer Ingelheim.
A.Electronic supplementary material
ESM 1
(DOCX 20 kb)
Supplementary Table 1
(DOCX 16 kb)
Supplementary Table 2
(DOCX 16 kb)
Supplementary Table 3
(DOCX 17 kb)
Supplementary Table 4
(DOCX 17 kb)
Supplementary Fig. 1
(PNG 129 kb)
Supplementary Fig. 2
(PNG 105 kb)
Supplementary Fig. 3
(PNG 118 kb)
Rights and permissions
About this article
Cite this article
Hiret, S., Isambert, N., Gomez-Roca, C. et al. Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors. Invest New Drugs 36, 1044–1059 (2018). https://doi.org/10.1007/s10637-018-0601-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-018-0601-1